WeVote
Log In

Bill

Bill

HB 3737

Relating to the prohibited prescription, delivery, administration, use, advertisement, and solicitation of a COVID-19 vaccine containing mRNA material.

89th Legislature (2025) Introduced by Caroline Harris Davila and 9 co-sponsors

Texas bill would ban prescription, administration, and promotion of mRNA-based COVID-19 vaccines, restricting healthcare provider options and vaccine availability.

Referred to Public Health
#advertising(s2680) #covid-19(sb9ym) #health--otherdiseases&medicalconditions(i0383) #immunizations(s4341) #medicine&prescriptiondrugs(s7338)
0
WeVote Research Nonpartisan
Bill Summary · HB 3737

Legislative bill overview

HB 3737 would prohibit the prescription, delivery, administration, use, advertisement, and solicitation of COVID-19 vaccines containing mRNA material in Texas. The bill appears designed to ban mRNA-based COVID-19 vaccines (such as those from Pfizer and Moderna) from being used or promoted within the state.

Why is this important

This would represent a significant restriction on vaccine availability and medical practice in Texas, potentially affecting public health infrastructure, healthcare provider autonomy, and individual medical choice. The bill could create legal liability for healthcare workers and facilities that administer these vaccines, which were authorized by the FDA and have been administered hundreds of millions of times globally.

Potential points of contention

  • Medical autonomy and liability: Healthcare providers typically have discretion in treatment options; this would override that judgment and could expose physicians to legal consequences for standard care practices
  • Public health authority conflict: Federal agencies (FDA, CDC) have approved these vaccines; state-level prohibition could create enforcement and coordination conflicts with federal health authorities
  • Scientific basis: The bill does not reference specific safety concerns; critics argue it restricts access to vaccines that regulatory agencies determined met safety and efficacy standards, while supporters have concerns about mRNA technology that this bill addresses
  • Practical implementation: Defining enforcement mechanisms, determining penalties, and handling patients who traveled for vaccination or received vaccines before the law took effect would present administrative challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.